Bladder Cancer in Spain 2011: Population Based Study
Por:
Minana, B, Cozar, JM, Palou, J, Urzaiz, MU, Medina-Lopez, RA, Rios, JS, de la Rosa-Kehrmann, F, Chantada-Abal, V, Lozano, F, Ribal, MJ, Fernandez, ER, Fernandez, JC, Masip, TC, Requena-Tapia, MJ, Moreno-Sierra, J, Hevia, M, Rodriguez, AG, Martinez-Ballesteros, C, Ramos, M, Sesmero, JHA, Reus, PP, Barrientos, AB, Sanz, CR, Gomez-Pascual, JA, Zabala, EH, Escobar, JLP, Serrano, O
Publicada:
1 feb 2014
Resumen:
Purpose: We estimate the annual incidence of bladder cancer in Spain and describe the clinical profile of patients with bladder cancer enrolled in a population based study.
Materials and Methods: Using the structure of the Spanish National Health System as a basis, in 2011 the AEU (Spanish Association of Urology) conducted this study with a representative sample from 26 public hospitals and a reference population of 10,146,534 inhabitants, comprising 21.5% of the Spanish population.
Results: A total of 4,285 episodes of bladder cancer were diagnosed, of which 2,476 (57.8%) were new cases and 1,809 (42.2%) were cases of recurrence, representing an estimated 11,539 new diagnoses annually in Spain. The incidence of bladder cancer in Spain, age adjusted to the standard European population, was 20.08 cases per 100,000 inhabitants (95% CI 13.9, 26.3). Of patients diagnosed with a first episode of bladder cancer 84.3% were male, generally older than 59 years (81.7%) with a mean +/- SD age of 70.5 +/- 11.4 years. Of these patients 87.5% presented with some type of clinical symptom, with macroscopic hematuria (90.8%) being the most commonly detected. The majority of primary tumors were nonmuscle invasive (76.7%) but included a high proportion of high grade tumors (43.7%). According to the ISUP (International Society of Urologic Pathology)/WHO (2004) classification 51.1% was papillary high grade carcinoma. Carcinoma in situ was found in 2.2% of primary and 5.8% of recurrent cases.
Conclusions: The incidence of bladder cancer in Spain, age adjusted to the standard European population, confirms that Spain has one of the highest incidences in Europe. Most primary nonmuscle invasive bladder cancer corresponded to high risk patients but with a low detected incidence of carcinoma in situ.
Filiaciones:
Minana, B:
Hospital Morales Meseguer, Murcia, Spain
Palou, J:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Masip, TC:
Hosp Univ Canarias, Dept Urol, Santa Cruz De Tenerife, Spain
Requena-Tapia, MJ:
Hosp Reina Sofia, Dept Urol, Cordoba, Spain
Moreno-Sierra, J:
Hosp Clin San Carlos, Dept Urol, Madrid, Spain
Hevia, M:
Hosp Univ Cent Asturias, Dept Urol, Oviedo, Spain
Rodriguez, AG:
Hosp Virgen de la Salud, Dept Urol, Toledo, Spain
Martinez-Ballesteros, C:
Hosp Puerta de Hierro, Dept Urol, Madrid, Spain
Ramos, M:
Univ Valencia, Dept Urol, Gen Hosp, Valencia, Spain
Sesmero, JHA:
Hosp Univ Rio Hortega, Dept Urol, Valladolid, Spain
Reus, PP:
Hosp Son Espases, Dept Urol, Mallorca, Spain
Barrientos, AB:
Hosp Doctor Peset, Dept Urol, Valencia, Spain
Sanz, CR:
Hosp Royo Villanova, Dept Urol, Zaragoza, Spain
Gomez-Pascual, JA:
Hosp Carlos Haya, Dept Urol, Malaga, Spain
Zabala, EH:
Hosp Univ Marques de Valdecilla, Dept Urol, Santander, Spain
Escobar, JLP:
Hosp Merida, Dept Urol, Badajoz, Spain
Serrano, O:
Gebro Pharm SA, Barcelona, Spain
|